• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

艰难梭菌感染对西班牙和意大利医院资源利用和成本的影响:一项匹配队列研究。

The impact of Clostridium difficile infection on resource use and costs in hospitals in Spain and Italy: a matched cohort study.

机构信息

Hospital Universitario Puerta de Hierro, C/ Manuel de Falla 1, Majadahonda 28222, Madrid, Spain; University Francisco de Vitoria, Madrid, Spain.

National Institute for Infectious Diseases "L. Spallanzani", Rome, Italy.

出版信息

Int J Infect Dis. 2015 Jul;36:31-8. doi: 10.1016/j.ijid.2015.05.013. Epub 2015 May 21.

DOI:10.1016/j.ijid.2015.05.013
PMID:26003403
Abstract

OBJECTIVE

To assess the impact of Clostridium difficile infection (CDI) on hospital resources and costs in Spain and Italy.

METHODS

CDI data were collected from institutions in Spain and Italy. Each patient was matched with two randomly selected uninfected controls in the same institution. Patient outcomes were assessed for the first and second episodes of CDI and for patients aged ≤65 and >65 years. The impact of CDI on hospital length of stay (LOS) was used to calculate CDI-attributable costs. A multivariate analysis using duration of stay as the continuous outcome variable assessed the independent effect of CDI on hospital costs and LOS.

RESULTS

LOS attributable to CDI ranged from 7.6-19.0 days in adults and was 5.0 days in children; the increases were greater in adults in Italy than in Spain. Attributable costs per adult patient ranged from €4396 in Madrid to €14 023 in Rome, with the majority of the cost being due to hospitalization. For children, the total attributable cost was €3545/patient.

CONCLUSIONS

These data show that the burden of CDI is considerable in Spain and Italy. Treatments that can reduce LOS, disease severity, and recurrence rates, as well as effective infection control measures to prevent transmission, have the potential to reduce the burden of CDI.

摘要

目的

评估艰难梭菌感染(CDI)对西班牙和意大利医院资源和成本的影响。

方法

从西班牙和意大利的医疗机构收集 CDI 数据。每个患者与同一机构中随机选择的两名未感染对照患者相匹配。评估了 CDI 第一和第二发作以及年龄≤65 岁和>65 岁患者的患者结局。使用住院时间来计算 CDI 相关成本,以评估 CDI 对住院费用和住院时间的独立影响。使用住院时间作为连续结果变量的多元分析评估了 CDI 对住院费用和住院时间的独立影响。

结果

成人归因于 CDI 的住院时间范围为 7.6-19.0 天,儿童为 5.0 天;意大利的成年人比西班牙的成年人增加更多。每位成年患者的归因费用从马德里的 4396 欧元到罗马的 14023 欧元不等,大部分费用归因于住院治疗。对于儿童,总归因费用为 3545 欧元/患者。

结论

这些数据表明,CDI 在西班牙和意大利的负担相当大。能够降低 LOS、疾病严重程度和复发率的治疗方法,以及有效的感染控制措施以预防传播,有可能减轻 CDI 的负担。

相似文献

1
The impact of Clostridium difficile infection on resource use and costs in hospitals in Spain and Italy: a matched cohort study.艰难梭菌感染对西班牙和意大利医院资源利用和成本的影响:一项匹配队列研究。
Int J Infect Dis. 2015 Jul;36:31-8. doi: 10.1016/j.ijid.2015.05.013. Epub 2015 May 21.
2
Hospitalization stay and costs attributable to Clostridium difficile infection: a critical review.艰难梭菌感染导致的住院时间和费用:一项批判性综述。
J Hosp Infect. 2014 Sep;88(1):12-21. doi: 10.1016/j.jhin.2014.04.011. Epub 2014 May 17.
3
Attributable Cost of Clostridium difficile Infection in Pediatric Patients.艰难梭菌感染患儿的归因成本。
Infect Control Hosp Epidemiol. 2017 Dec;38(12):1472-1477. doi: 10.1017/ice.2017.240. Epub 2017 Nov 27.
4
Burden of Clostridium difficile Infections in French Hospitals in 2014 From the National Health Insurance Perspective.从国家医疗保险角度看2014年法国医院艰难梭菌感染的负担
Infect Control Hosp Epidemiol. 2017 Aug;38(8):906-911. doi: 10.1017/ice.2017.114.
5
Evaluation of fixed and variable hospital costs due to Clostridium difficile infection: institutional incentives and directions for future research.艰难梭菌感染所致固定和可变医院成本评估:机构激励措施及未来研究方向
J Hosp Infect. 2017 Apr;95(4):415-420. doi: 10.1016/j.jhin.2017.01.016. Epub 2017 Feb 2.
6
Economic burden of primary compared with recurrent Clostridium difficile infection in hospitalized patients: a prospective cohort study.住院患者中初次与复发性艰难梭菌感染的经济负担:一项前瞻性队列研究。
J Hosp Infect. 2016 Jul;93(3):286-9. doi: 10.1016/j.jhin.2016.04.004. Epub 2016 Apr 20.
7
Hospital cost of Clostridium difficile infection including the contribution of recurrences in French acute-care hospitals.艰难梭菌感染在法国急症医院的住院费用,包括复发造成的费用。
J Hosp Infect. 2015 Oct;91(2):117-22. doi: 10.1016/j.jhin.2015.06.017. Epub 2015 Jul 22.
8
Inpatient Expenditures Attributable to Hospital-Onset Clostridium difficile Infection: A Nationwide Case-Control Study in Japan.与医院获得性艰难梭菌感染相关的住院费用:日本全国范围内的病例对照研究。
Pharmacoeconomics. 2018 Nov;36(11):1367-1376. doi: 10.1007/s40273-018-0692-8.
9
Trend, Risk Factors, and Costs of Clostridium difficile Infections in Vascular Surgery.血管外科艰难梭菌感染的趋势、危险因素及成本
Ann Vasc Surg. 2015;29(4):792-800. doi: 10.1016/j.avsg.2014.10.031. Epub 2015 Jan 14.
10
Impact of Clostridium difficile-associated diarrhea on acute care length of stay, hospital costs, and readmission: A multicenter retrospective study of inpatients, 2009-2011.艰难梭菌相关性腹泻对急性护理住院时间、医院成本和再入院的影响:一项针对2009 - 2011年住院患者的多中心回顾性研究。
Am J Infect Control. 2015 Nov;43(11):1148-53. doi: 10.1016/j.ajic.2015.06.004.

引用本文的文献

1
Management of Clostridioides difficile infection: an Italian Delphi consensus.艰难梭菌感染的管理:意大利德尔菲共识。
J Antimicrob Chemother. 2024 Sep 3;79(9):2103-2118. doi: 10.1093/jac/dkae179.
2
Infection in Hospitalized Patients-A Retrospective Epidemiological Study.住院患者感染——一项回顾性流行病学研究
Healthcare (Basel). 2023 Dec 29;12(1):76. doi: 10.3390/healthcare12010076.
3
Economic Burden of Clostridioides difficile Infection in European Countries.欧洲国家艰难梭菌感染的经济负担。
Adv Exp Med Biol. 2024;1435:1-12. doi: 10.1007/978-3-031-42108-2_1.
4
A Comparison of the Efficacy of Treatment With Fidaxomicin Versus Vancomycin in Clostridioides difficile Infection.非达霉素与万古霉素治疗艰难梭菌感染的疗效比较
Cureus. 2023 Nov 13;15(11):e48735. doi: 10.7759/cureus.48735. eCollection 2023 Nov.
5
Real-world Use of Bezlotoxumab and Fecal Microbiota Transplantation for the Treatment of Infection.贝佐妥昔单抗和粪便微生物群移植在感染治疗中的实际应用。
Open Forum Infect Dis. 2023 Jan 25;10(2):ofad028. doi: 10.1093/ofid/ofad028. eCollection 2023 Feb.
6
Improving care for patients with infection: A clinical practice and healthcare systems perspective.改善感染患者的护理:临床实践与医疗保健系统视角
Front Med (Lausanne). 2023 Jan 12;9:1033417. doi: 10.3389/fmed.2022.1033417. eCollection 2022.
7
Economic burden and cost-effectiveness of therapies for infection: a narrative review.感染治疗的经济负担和成本效益:一项叙述性综述
Therap Adv Gastroenterol. 2021 May 30;14:17562848211018654. doi: 10.1177/17562848211018654. eCollection 2021.
8
Economic burden of recurrent Clostridioides difficile infection in adults admitted to Spanish hospitals. A multicentre retrospective observational study.西班牙医院成人复发性艰难梭菌感染的经济负担:一项多中心回顾性观察研究。
Rev Esp Quimioter. 2021 Apr;34(2):126-135. doi: 10.37201/req/135.2020. Epub 2021 Feb 23.
9
Analysis of C. difficile infection-related outcomes in European participants in the bezlotoxumab MODIFY I and II trials.贝洛妥珠单抗 MODIFY I 和 II 临床试验中欧洲参与者艰难梭菌感染相关结局分析。
Eur J Clin Microbiol Infect Dis. 2020 Oct;39(10):1933-1939. doi: 10.1007/s10096-020-03935-3. Epub 2020 Jun 6.
10
Thirty-Day Readmissions in Hospitalized Patients Who Received Bezlotoxumab With Antibacterial Drug Treatment for Clostridium difficile Infection.接受 bezlotoxumab 联合抗菌药物治疗艰难梭菌感染的住院患者的 30 天再入院率。
Clin Infect Dis. 2017 Oct 1;65(7):1218-1221. doi: 10.1093/cid/cix523.